Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Bullboard Posts
Post by CUR2004on Mar 04, 2011 3:21pm
220 Views
Post# 18234219

1$...

1$...Hi,

I really don't understand why we are at 1$ with a market cap of less than 50 millions when we are so close of the goal.

I was a shareholder between 2004 and october 2006. From this time I continue to follow Diagnocure to see the development of the company and wait for the FDA request.

Last week I become a shareholder again rebuy all the share I have in 2006. I think all we are waiting for in 2006 is just at the corner. 

Do you know how close we are of the 16% redevance? 600 000$ of redevance at 8% equal sales of 7.5 millions for Gen-Probe in 2010. If I remember after 50-57 millions of cumulative sales we will be at 16%.

If Gen-Probe do 7.5 millions sales only in Europe and with the ASR in USA, what is your expectations for the year following the FDA approval? And thes sales in Austria and Japan?

I really don't understand why Gen-Probe don't buy Diagnocure at this time. Imagine if a competitor do a takeover on Diagnocure, Gen-Probe will have to give 16% of is sales to them???? This could be a nice investment. Keep the rights on PCA3 and sale the balance.

Which one of you will be at the annual meeting next week?
Bullboard Posts